AstraZeneca Ordered to Pay Pfizer Over $107 Million in Tagrisso Patent Infringement Case

1. A jury in the United States District Court for the District of Delaware found that AstraZeneca infringed on Pfizer's patent related to the lung cancer drug Tagrisso (osimertinib).
2. The jury awarded Pfizer $107 million in damages for AstraZeneca's infringement, which could potentially increase with interest and additional fees.
3. Tagrisso is a medication used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations, and it has been a significant source of revenue for AstraZeneca.
4. Pfizer originally filed the lawsuit against AstraZeneca in 2019, alleging that Tagrisso infringed on its patent covering a method of treating NSCLC using a specific class of drugs.
5. The verdict marks a significant win for Pfizer in the ongoing battle against AstraZeneca over the intellectual property rights of lung cancer treatments.
6. AstraZeneca has stated that it plans to appeal the jury's decision, arguing that the patent in question is invalid and that Tagrisso does not infringe on Pfizer's intellectual property.